Patient baseline demographics and clinical characteristics
| Patient baseline characteristics | N = 46,490 episodes of care |
|---|---|
| Age, Yrs, mean (std) | 49 (13) |
| Female, N, % | 35 330 (76%) |
| Comorbidities | |
| Hypertension, n (%) | 13 283 (29%) |
| Diabetes, n (%) | 4 529 (10%) |
| Charlson score*, mean (std) | 1.0 (0.9) |
| Filled prescription for select medications | |
| Statins, n (%) | 7 952 (17%) |
| Non-statin lipid lowering medications, n (%) | 2 205 (5%) |
| Anti-TNF biologics, n (%) | 7 034 (15%) |
| Non-TNF biologics, n (%) | 73 (0.2%) |
| Methotrexate, n (%) | 14 337 (31%) |
| Non-methotrexate DMARDs, n (%) | 10 612 (23%) |
| Average oral prednisone-equivalent glucocorticoid dose, n (%) | |
| None | 28 929 (62%) |
| > 0 and ≤ 7.5 mg/d | 15 037 (32%) |
| >7.5 and ≤ 20 mg/d | 2 318 (5%) |
| >20 mg/d | 206 (0.4%) |
| Distribution of lab values | |
| CRP, mg/L, median (IQR) | 2.9 (6.5) |
| ESR, mm/hr, median, (IQR) | 8 (15) |
| LDL, mg/dL [mmol/L], median (IQR) | 108 (45) [2.8 (1.2)] |
| HDL, mg/dL[mmol/L], median (IQR) | 51 (20) [1.3 (0.5)] |
*A summary comorbidity score to predict short-term mortality and other significant clinical outcomes.27
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TNF, tumour necrosis factor.